ValueLabs Wins Nine Globee® Awards, Validates Position as Agentic AI Services Leader
HYDERABAD, India, May 26, 2025 /CNW/ -- ValueLabs has been recognized at the 2025 Globee® Awards for Artificial Intelligence, winning eight Gold and one Bronze awards across key categories. This recognition reinforces the company's position as an Agentic AI Services company and their standing as a true Category of One.
When Generative AI burst onto the scene 28 months ago, ValueLabs saw it as both an existential threat and a once-in-a-generation opportunity for reinvention. Their response was immediate and decisive.
They declared their traditional business model obsolete and built AiDE®, their Enterprise Operating System, which now powers every function of the organization. With full internal adoption, they are able to deliver solutions at unprecedented speed and scale.
AiDE® acts like an 'Ironman suit' for their designers, architects, developers, and testers — amplifying productivity, improving quality, and making the art of the possible come alive. This democratization of expertise has fundamentally transformed how their teams operate across the entire software development lifecycle.
Beyond traditional AI use cases, their Vertical AI consulting and solutions enable enterprises to reimagine their entire business models for an AI-first world. By combining deep domain expertise with Agentic AI capabilities, they help organizations transform industry-specific processes into intelligent, autonomous workflows that drive measurable business outcomes.
This recognition by the Globee® Awards across a wide spectrum of categories underlines the platform's versatility and real-world impact across industries. ValueLabs was awarded in the following categories:
Gold Awards:
Artificial Intelligence Company of the Year: ValueLabs
Best Achievement in Artificial Intelligence Operations: AiDE Operations
Best AI Platform: AiDE®
Best AI-driven Personalization Solution: AiDE UX
Best AI-driven Automated Testing Solution: AiDE QE
Best AI-powered Customer Insights Solution: AiDE Conversational Insights
AI-Driven Threat Detection: AiDE Shield
Most Innovative Artificial Intelligence Tool for Customer Service: AiDE Chat
Bronze Award:
Best AI-based Knowledge Management Solution: AiDE Academy
"These awards reflect the natural evolution of our 28-year journey," said Arjun Rao, Founder and Chairman, ValueLabs. "We are not just implementing AI. We are reimagining entire value chains and building autonomous capability across every function. Our move into Agentic AI Services is not a reaction to the moment — it is a continuation of everything we have been building toward."
Sam Alva, CEO, ValueLabs, noted, "We're practicing what we preach. AiDE® transforms every aspect of our business — from how our consulting teams shape strategy to how our delivery teams bring strategy to life. It powers how we build proposals, onboard clients, and drive outcomes at scale. Our Vertical AI solutions are opening new possibilities for clients to reimagine their industry-specific challenges with intelligence and speed. The recognition from the Globee® Awards, along with recent honors from Stevie and World HRD awards, affirms that we have moved from the art of the possible to the science of the real."
The company's approach reflects what many now refer to as 'Service-as-Software' — transforming work once done traditionally, manually into intelligent systems that deliver outcomes at scale. This model allows enterprises to rethink how to operate in an AI-first world.
With more than 7,000 employees worldwide, ValueLabs helps organizations move beyond tool adoption to become truly AI-native businesses. While research shows that 87 percent of enterprises are still in the pilot phase with AI, ValueLabs has reached full production scale across its own operations. The nine Globee® Awards underscore the company's unique position at the intersection of traditional consulting, cutting-edge technology, and Agentic AI delivery across both horizontal platforms and vertical industry solutions.
About ValueLabs
Founded in 1997, ValueLabs is a global Agentic AI Services company helping enterprises transition into AI-native businesses. At the core of this transformation is AiDE® — our proprietary platform for AI Driven Everything. This enterprise-grade platform functions as an OS for intelligent work across engineering, operations, and business functions.
With AiDE®, we've created a category of our own: combining platform innovation, consulting depth, and outcome-based delivery to solve enterprise-scale challenges. From strategy to execution, we design and deploy tailored AI solutions through both horizontal capabilities and vertical industry offerings.
With a Client NPS of 90 and an Employee NPS of 80, our relationships are built on trust, measurable impact, and long-term value creation.
Logo: https://mma.prnewswire.com/media/1343811/ValueLabs_Logo.jpg
View original content:https://www.prnewswire.com/news-releases/valuelabs-wins-nine-globee-awards-validates-position-as-agentic-ai-services-leader-302465196.html
SOURCE ValueLabs LLP
View original content: http://www.newswire.ca/en/releases/archive/May2025/26/c0745.html
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
29 minutes ago
- Yahoo
Roche's Tecentriq combined with lurbinectedin shows significant survival benefit in extensive-stage small cell lung cancer
46% reduction in the risk of disease progression or death, and 27% reduction in the risk of death, in an aggressive cancer type with limited survival and few treatment options 1 First Phase III study in ES-SCLC first-line maintenance to demonstrate clinically meaningful improvements in both progression-free and overall survival 2,3 Data were presented in an oral session at the 2025 ASCO Annual Meeting and simultaneously published in The Lancet 1,4 Basel, 3 June 2025 - Roche (SIX: RO, ROG; OTCQX: RHHBY) announced today positive results from the Phase III IMforte study of Tecentriq® (atezolizumab) in combination with lurbinectedin (Zepzelca®) as a first-line maintenance treatment for people with extensive-stage small cell lung cancer (ES-SCLC), following induction therapy with carboplatin, etoposide and Tecentriq. The data showed that this combination reduced the risk of disease progression or death by 46% and the risk of death by 27%, compared to Tecentriq maintenance therapy alone. Safety was consistent with the known safety profiles of Tecentriq and lurbinectedin. These data were presented in an oral session at the 2025 American Society of Clinical Oncology (ASCO) Annual Meeting and simultaneously published in The Lancet.1,4 "Small cell lung cancer is an aggressive and devastating disease. At the time of diagnosis, the large majority of patients have already progressed to extensive-stage disease and only one out of five survive longer than two years', said Luis Paz-Ares, MD, PhD, Head of Medical Oncology at the Hospital Universitario 12 de Octubre in Madrid, Spain, and IMforte trial principal investigator. 'The IMforte results are very encouraging showing a potentially practice-changing option that could improve survival for patients with a very high unmet need.' "In the IMforte study, the Tecentriq and lurbinectedin maintenance regimen significantly extended survival for people living with extensive-stage small cell lung cancer,' said Levi Garraway, MD, PhD, Roche's Chief Medical Officer and Head of Global Product Development. 'This study builds on Tecentriq's well-established safety and efficacy profile as the first immunotherapy for this cancer type and may provide another approach to help physicians and patients better manage this aggressive disease." Patients in the IMforte study first completed four cycles of Tecentriq combined with chemotherapy, over the course of approximately three months, before being randomised into maintenance treatment. From the point of randomisation, the median overall survival (OS) for the Tecentriq plus lurbinectedin regimen was 13.2 months versus 10.6 months for Tecentriq alone (stratified hazard ratio [HR] = 0.73; 95% CI: 0.57–0.95; p = 0.0174). Median progression-free survival (PFS) by independent assessment was 5.4 months versus 2.1 months, respectively (stratified HR = 0.54, 95% CI: 0.43–0.67; p < 0.0001). No new safety signals were observed.1 About the IMforte study IMforte [NCT05091567] is a Phase III, open-label, randomised trial evaluating the efficacy and safety of Tecentriq® (atezolizumab) plus lurbinectedin versus Tecentriq alone as first-line maintenance therapy for adults (≥18 years) with extensive-stage small-cell lung cancer (ES-SCLC). Patients first received induction therapy with Tecentriq, carboplatin and etoposide for four 21-day cycles. Those without disease progression were then randomised 1:1 to receive maintenance therapy with either Tecentriq plus lurbinectedin or Tecentriq alone until disease progression or unacceptable toxicity. The study enrolled 660 patients in the induction phase and randomised 483 patients in the maintenance phase. The study's primary endpoints were independent review facility (IRF)-assessed progression-free survival (PFS) and overall survival (OS) from randomisation into the maintenance phase.1,5 The trial is sponsored by Roche and co-funded by Jazz Pharmaceuticals. About Tecentriq Tecentriq is a monoclonal antibody designed to bind with a protein called PD-L1. Tecentriq is designed to bind to PD-L1 expressed on tumour cells and tumour-infiltrating immune cells, blocking its interactions with both PD-1 and B7.1 receptors. By inhibiting PD-L1, Tecentriq may enable the re-activation of T cells. Tecentriq may also affect normal cells. Tecentriq is approved for some of the most aggressive and difficult-to-treat forms of cancer. Tecentriq was the first cancer immunotherapy approved for the treatment of a certain type of early-stage (adjuvant) NSCLC, small cell lung cancer (SCLC) and hepatocellular carcinoma (HCC). Tecentriq is also approved in countries around the world, either alone or in combination with targeted therapies and/or chemotherapies, for various forms of metastatic NSCLC, certain types of metastatic urothelial cancer (mUC), PD-L1-positive metastatic triple-negative breast cancer (TNBC), BRAF V600 mutation-positive advanced melanoma and alveolar soft part sarcoma (ASPS). In addition to intravenous infusion, Tecentriq has been approved as a subcutaneous injection. About Roche in cancer immunotherapy To learn more about Roche's scientific-led approach to cancer immunotherapy, please follow this link: Roche Founded in 1896 in Basel, Switzerland, as one of the first industrial manufacturers of branded medicines, Roche has grown into the world's largest biotechnology company and the global leader in in-vitro diagnostics. The company pursues scientific excellence to discover and develop medicines and diagnostics for improving and saving the lives of people around the world. We are a pioneer in personalised healthcare and want to further transform how healthcare is delivered to have an even greater impact. To provide the best care for each person we partner with many stakeholders and combine our strengths in Diagnostics and Pharma with data insights from the clinical practice. For over 125 years, sustainability has been an integral part of Roche's business. As a science-driven company, our greatest contribution to society is developing innovative medicines and diagnostics that help people live healthier lives. Roche is committed to the Science Based Targets initiative and the Sustainable Markets Initiative to achieve net zero by 2045. Genentech, in the United States, is a wholly owned member of the Roche Group. Roche is the majority shareholder in Chugai Pharmaceutical, Japan. For more information, please visit ZEPZELCA is a trademark of Pharma Mar, S.A. used by Jazz Pharmaceuticals under license. All trademarks used or mentioned in this release are protected by law. References [1] Paz-Ares L, et al. Lurbinectedin (lurbi) + atezolizumab (atezo) as first-line (1L) maintenance treatment (tx) in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC): Primary results of the phase 3 IMforte trial. Presented at: ASCO Annual Meeting; 2025 May 30-Jun 03; Chicago, IL, USA. Abstract #8006. [2] Belluomini L, et al. Maintenance or consolidation therapy in small-cell lung cancer: an updated systematic review and meta-analysis. Seminars in Oncology. 2022; 49(5): 389-393. [3] Roviello G, et al. No advantage in survival with targeted therapies as maintenance in patients with limited and extensive-stage small cell lung cancer: a literature-based meta-analysis of randomized trials. Clin Lung Cancer. 2016; 17(5): 334–340. [4] Paz-Ares L, et al. Efficacy and safety of first-line maintenance therapy with lurbinectedin plus atezolizumab in extensive-stage small-cell lung cancer (IMforte): a randomised, multicentre, open-label, phase 3 trial. Lancet. 2025 Jun 02. [Internet; cited June 2025]. Available from: [5] A Phase III, Open-Label Study of Maintenance Lurbinectedin in Combination With Atezolizumab Compared With Atezolizumab in Participants With Extensive-Stage Small-Cell Lung Cancer (IMforte). [Internet; cited May 2025]. Available from: Roche Global Media Relations Phone: +41 61 688 8888 / e-mail: Hans Trees, PhD Phone: +41 79 407 72 58 Sileia Urech Phone: +41 79 935 81 48 Nathalie Altermatt Phone: +41 79 771 05 25 Lorena Corfas Phone: +41 79 568 24 95 Simon Goldsborough Phone: +44 797 32 72 915 Karsten Kleine Phone: +41 79 461 86 83 Nina Mählitz Phone: +41 79 327 54 74 Kirti Pandey Phone: +49 172 6367262 Yvette Petillon Phone: +41 79 961 92 50 Dr Rebekka Schnell Phone: +41 79 205 27 03 Roche Investor Relations Dr Bruno Eschli Phone: +41 61 68-75284 e-mail: Dr Sabine Borngräber Phone: +41 61 68-88027 e-mail: Dr Birgit Masjost Phone: +41 61 68-84814 e-mail: Investor Relations North America Loren Kalm Phone: +1 650 225 3217 e-mail: Attachment 03062025_Phase III IMforte study of Tecentriq_enError in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Vectra AI Named a Leader in the First-Ever Gartner® Magic Quadrant for Network Detection and Response
Recognized for the Strength of its AI-Driven NDR Platform, Vectra AI is Positioned Furthest for Completeness of Vision and Highest for Ability to Execute in the Inaugural Report SINGAPORE, June 3, 2025 /PRNewswire/ -- Vectra AI, Inc., the cybersecurity AI company that protects modern networks from modern attacks, today announced it was named a Leader in the 2025 Gartner® Magic Quadrant for Network Detection and Response (NDR). Vectra AI is positioned highest for Ability to Execute and furthest for Completeness of Vision, and is the only vendor in the report to be named a leader in both the Gartner Magic Quadrant for NDR and a Customer Choice Winner for NDR in the 2024 Gartner Peer Insights Voice of the Customer. The Vectra AI Platform is purpose-built to defend modern hybrid environments from identity and network-based attacks. As threats accelerate across cloud, data center, remote, and OT domains, Vectra AI provides comprehensive coverage to reduce attack exposure. Its AI agents continuously triage, correlate, and prioritize real threats in real time – eliminating alert fatigue and accelerating response. With Vectra AI, defenders gain control to detect, hunt, investigate, and respond to attacks across the full threat landscape, enabling security teams to focus on maturing their security posture. "Gartner's decision to publish a Magic Quadrant for NDR reflects just how essential this market has become in modern cyber defense," said Hitesh Sheth, founder and CEO of Vectra AI. "Being recognized as a Leader in this inaugural report reinforces Vectra AI's position at the forefront of this critical space. As organizations grapple with growing complexity, identity-based attacks, and AI-driven threats, the Vectra AI Platform delivers what modern defenders need – coverage that reduces exposure, clarity that cuts through the noise, and control to act with speed and confidence." Vectra AI has been recognized by customers for outstanding product performance and support, earning the distinction of Customers' Choice in the 2024 Gartner® Peer Insights™ Voice of the Customer for Network Detection and Response. As of January 2024, Vectra AI holds a 4.8 out of 5 rating based on 96 reviews, with 96% of customers saying they would recommend the platform. This recognition reflects Vectra AI's deep commitment to customer success and ongoing innovation in protecting modern networks from modern attacks. Download the full Magic Quadrant for Network Detection and Response here. View original content: SOURCE Vectra AI Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
3 hours ago
- Yahoo
Self Storage Awards Asia Gala Dinner announces winners at Self Storage Expo Asia 2025
HONG KONG, June 3, 2025 /PRNewswire/ -- The Self Storage Association Asia announces the Self Storage Association Awards Asia 2025 winners in Tokyo. The Awards recognise Asia-wide and local excellence in self storage in customer service, the use of technology and other key industry metrics. Industry leaders across Asia are raising safety standards, customer service and good governance. Consumers, investors and governments can look to the award winners for the gold standard in self storage in Asia. Self storage is proving a vital industry for empowering small and large businesses to grow through flexible use of space for modern economies. The full list of finalists and details of the entries are at the Awards website at Multi-Site Operator Store of the Year recognises the best self storage site in Asia operated by a large company. Winner Asia & Singapore: Work+Store Regional winners: Hong Kong SAR: RedBox Storage The Philippines: Loc&Stor 24/7 Sucat Independent Store of the Year recognises the best self storage site in Asia operated by a smaller company. Independent Store of the Year & La Réunion Winner: IZIBOX Regional winners: The Philippines: INSTORAGE BY CLAIRMONT Jordan: Easy Storage Jordan Valet Storage of the Year recognises the best valet storage company in Asia providing door-to-door service. Winner Asia and Hong Kong: Valet Stored! Manager of the Year recognises an on-site manager who has outperformed their peers across Asia. Winner Asia and Japan: Quraz - Rumiko Uchida Regional winners: Singapore: Lock+Store - Soh Xun Ling Hong Kong SAR: The Store House - Walter Wu The Environmental, Social, and Governance Initiative Award (ESG Award) recognises excellence in initiatives advancing ESG goals. Winner Asia and Japan: Arealink Co.,Ltd / Hello Storage Regional winners: Singapore: StorHub Self Storage The Philippines: INSTORAGE BY CLAIRMONT Dubai: The Box Self Storage La Réunion: IZIBOX Hong Kong SAR: Storefriendly The Technology & Innovation Award recognises the implementation of technology in operations or customer service above and beyond industry standards. Winner Asia and Thailand: LEO Self Storage Regional winners: Vietnam: MyStorage Vietnam Hong Kong SAR: Storefriendly The Creative & Effective Marketing Award recognises novel thinking that delivers results in driving sales through marketing. Winner Asia and Singapore: Work+Store Regional winner: La Réunion: IZIBOX The Customer Experience Satisfaction Award recognises operators who have demonstrated outstanding service levels, customer care, and user experience, setting new standards in customer satisfaction. Winner Asia and Thailand: i-Store Self Storage Regional winners: The Philippines: INSTORAGE BY CLAIRMONT Hong Kong SAR: RedBox Storage About the Self Storage Association Asia The SSAA is the industry body representing and serving the self storage industry in Asia from Japan to Jordan. Its members comprise the best of class self storage operators, their suppliers and investors. The SSAA provides training, advocacy, intelligence, market reports and a networking platform to help operators to continue to improve and grow. View original content to download multimedia: SOURCE SELF STORAGE ASSOCIATION
